Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALNGet Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 42,400 shares, a growth of 49.8% from the February 29th total of 28,300 shares. Based on an average trading volume of 10,000 shares, the short-interest ratio is currently 4.2 days. Currently, 0.1% of the company’s shares are sold short.

Hedge Funds Weigh In On Valneva

Several institutional investors have recently bought and sold shares of the business. UBS Group AG purchased a new position in Valneva during the second quarter valued at approximately $31,000. Bank of America Corp DE purchased a new position in Valneva during the first quarter valued at approximately $858,000. Finally, Jane Street Group LLC increased its holdings in Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock valued at $569,000 after buying an additional 7,664 shares during the period. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Stock Performance

Shares of VALN stock opened at $7.92 on Friday. The firm has a market cap of $550.12 million, a price-to-earnings ratio of -5.01 and a beta of 2.23. The company’s 50 day moving average is $7.71 and its 200 day moving average is $10.09. The company has a quick ratio of 1.37, a current ratio of 1.65 and a debt-to-equity ratio of 1.04. Valneva has a 52-week low of $6.58 and a 52-week high of $17.05.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Valneva in a research note on Thursday, March 21st. Guggenheim decreased their price target on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, March 22nd.

Check Out Our Latest Stock Report on Valneva

About Valneva

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

Recommended Stories

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with's FREE daily email newsletter.